EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies

Courtney D DiNardo iD, Rebecca Olin, Eunice S Wang, Barry Skikne, Joseph Rosenthal, Prasanna Kumar, Hiroyuki Sumi, Yoshiyuki Hizukuri, Ying Hong, Parul Patel, Takahiko Seki, Tao Duan und 2 weitere

Cancer Medicine · 2024

DOI: 10.1002/cam4.70028 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer Medicine, 2024. Verfasst von Courtney D DiNardo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Azacitidine, Proto-Oncogene Proteins c-mdm2, Antineoplastic Combined Chemotherapy Protocols, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mouse double minute‐2 homolog (MDM2) plays a key role in downregulating p53 activity in hematologic malignancies, and its overexpression is associated with poor outcomes.

Methods

This phase 1 study assessed the safety and efficacy of different dosing regimens of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine (AZA) in patients with relapsed or refractory acute myeloid leukemia or high‐risk myelodysplastic syndromes.

Results

Seventy‐four patients (monotherapy, n = 57; milademetan‐AZA combination, n = 17) were treated. The maximum tolerated dose of milademetan was 160 mg once daily given for the first 14–21 days of 28‐day cycles as monotherapy and on Days 5–14 in combination with AZA. Dose‐limiting toxicities were gastrointestinal, fatigue, or renal/electrolyte abnormalities. Treatment‐emergent adverse events related to milademetan occurred in 82.5% and 64.7% of participants in the monotherapy and AZA combination arms, respectively. Two participants (4.2%) in the monotherapy arm achieved complete remission (CR), and 1 (2.1%) achieved CR with incomplete blood count recovery (CRi). Two participants (13.3%) achieved CRi in the combination arm. New TP53 mutations, detected only during milademetan monotherapy, were found pre‐existing below standard detection frequency by droplet digital polymerase chain reaction.

Interpretation

Milademetan was relatively well tolerated in this population; however, despite signals of activity, clinical efficacy was minimal.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzacitidineProto-Oncogene Proteins c-mdm2Antineoplastic Combined Chemotherapy ProtocolsLeukemia, Myeloid, AcuteMaximum Tolerated DoseMyelodysplastic SyndromesHumansMaleFemaleAgedMiddle AgedAged, 80 and overAdultTreatment OutcomeCarbolinesHeterocyclic Compounds, 4 or More Rings

Stichwörter der Autor:innen

acute myeloid leukemiamilademetanmouse double minute‐2 homologmyelodysplastic syndromes

Substanzen

AzacitidineProto-Oncogene Proteins c-mdm2MDM2 protein, humanPM 01183CarbolinesHeterocyclic Compounds, 4 or More Rings

Autor:innen und Institutionen

  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • University of California, San Francisco, California, USA.
  • Roswell Park Comprehensive Care Center, Buffalo, New York, USA.
  • University of Kansas Medical Center, Kansas City, Kansas, USA.
  • Department of Pediatrics, City of Hope, Duarte, California, USA.
  • Daiichi Sankyo Inc., Basking Ridge, New Jersey, USA.

ORCID-Profile: Courtney D DiNardo

Zitieren

APA

DiNardo, C. D., Olin, R., Wang, E. S., Skikne, B., Rosenthal, J., Kumar, P., Sumi, H., Hizukuri, Y., Hong, Y., Patel, P., Seki, T., Duan, T., Lesegretain, A., & Andreeff, M. (2024). Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies. Cancer Medicine. https://doi.org/10.1002/cam4.70028

Vancouver

DiNardo CD, Olin R, Wang ES, Skikne B, Rosenthal J, Kumar P, et al. Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies. Cancer Medicine. 2024. doi:10.1002/cam4.70028

BibTeX
@article{DiNardo2024,
  author = {DiNardo, Courtney D and Olin, Rebecca and Wang, Eunice S and Skikne, Barry and Rosenthal, Joseph and Kumar, Prasanna and Sumi, Hiroyuki and Hizukuri, Yoshiyuki and Hong, Ying and Patel, Parul and Seki, Takahiko and Duan, Tao and Lesegretain, Arnaud and Andreeff, Michael},
  title = {Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.70028}
}
Kostenlos starten →